Re:
|
AMN Healthcare Services, Inc.
Form 10-K for the Year Ended December 31, 2018
Filed February 21, 2019
Form 8-K filed October 31, 2019
File No. 001-167533 |
1.
|
Please quantify all variance factors cited pursuant to section 501.04 of staff's Codification of Financial
Reporting so that investors may readily understand the magnitude of each. Also, please note citing factors such as operating results and changes in balance sheet items may not provide a sufficient basis to understand how operating cash
between comparative periods was affected and varied. In this regard, supplement your analysis with the material drivers underlying the factors cited, as appropriate. Refer to section IV.B.1 of Release No. 33-8350 for guidance.
|
2.
|
Please revise the format of your non-GAAP reconciliations here and for the applicable guidance to
reconcile from the most comparable GAAP measure to the corresponding non-GAAP measure for equal or greater prominence of the GAAP measure. Refer to Question 102.10 of the staff’s Compliance and Disclosure Interpretations “Non-GAAP Financial
Measures” for guidance.
|
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||||||
|
September 30,
|
June 30,
|
September 30,
|
|||||||||||||||||
|
2019
|
2018
|
2019
|
2019
|
2018
|
|||||||||||||||
Revenue
|
||||||||||||||||||||
Nurse and allied solutions
|
$
|
362,533
|
$
|
306,292
|
$
|
331,627
|
$
|
1,031,189
|
$
|
977,199
|
||||||||||
Locum tenens solutions
|
84,164
|
101,102
|
82,074
|
246,728
|
311,516
|
|||||||||||||||
Other workforce solutions
|
120,900
|
119,448
|
121,476
|
357,298
|
318,724
|
|||||||||||||||
|
$
|
567,597
|
$
|
526,842
|
$
|
535,177
|
$
|
1,635,215
|
$
|
1,607,439
|
||||||||||
|
||||||||||||||||||||
Reconciliation of Non-GAAP Items:
|
||||||||||||||||||||
|
||||||||||||||||||||
Net income
|
$
|
23,515
|
$
|
27,918
|
$
|
28,869
|
86,506
|
$
|
106,128
|
|||||||||||
Income tax expense
|
8,394
|
10,068
|
10,222
|
23,873
|
30,163
|
|||||||||||||||
Income before income taxes
|
31,909
|
37,986
|
39,091
|
110,379
|
136,291
|
|||||||||||||||
Interest expense, net, and other
|
7,830
|
4,649
|
6,065
|
19,568
|
16,360
|
|||||||||||||||
Income from operations
|
39,739
|
42,635
|
45,156
|
129,947
|
152,651
|
|||||||||||||||
Depreciation and amortization
|
17,085
|
11,296
|
12,718
|
41,513
|
29,788
|
|||||||||||||||
Share-based compensation (1)
|
2,825
|
1,809
|
3,702
|
11,713
|
7,954
|
|||||||||||||||
Acquisition, integration, and other costs (2)
|
9,602
|
(452
|
)
|
5,156
|
18,787
|
1,474
|
||||||||||||||
Legal settlement accrual increases (3)
|
—
|
12,140
|
—
|
—
|
12,140
|
|||||||||||||||
Adjusted EBITDA (4)
|
$
|
69,251
|
$
|
67,428
|
$
|
66,732
|
$
|
201,960
|
$
|
204,007
|
||||||||||
Adjusted EBITDA margin (5)
|
12.2
|
%
|
12.8
|
%
|
12.5
|
%
|
12.4
|
%
|
12.7
|
%
|
||||||||||
Segment operating income (6)
|
||||||||||||||||||||
Nurse and allied solutions
|
$
|
47,544
|
$
|
42,165
|
$
|
48,694
|
$
|
144,160
|
$
|
137,906
|
||||||||||
Locum tenens solutions
|
6,156
|
10,992
|
7,128
|
18,985
|
34,321
|
|||||||||||||||
Other workforce solutions
|
27,806
|
29,010
|
27,127
|
81,121
|
77,437
|
|||||||||||||||
|
81,506
|
82,167
|
82,949
|
244,266
|
249,664
|
|||||||||||||||
Unallocated corporate overhead
|
12,255
|
14,739
|
16,217
|
42,306
|
45,657
|
|||||||||||||||
Adjusted EBITDA (4)
|
$
|
69,251
|
$
|
67,428
|
$
|
66,732
|
$
|
201,960
|
$
|
204,007
|
||||||||||
|
|
Three Months Ended
|
|||
|
December 31, 2019
|
|||
|
||||
Operating margin
|
8.2
|
%
|
||
Depreciation and amortization
|
3.0
|
%
|
||
EBITDA margin
|
11.2
|
%
|
||
Share-based compensation
|
0.6
|
%
|
||
Acquisition, integration, and other costs
|
0.2
|
%
|
||
Adjusted EBITDA margin (7)
|
12.0
|
%
|
(1) |
Share-based compensation for the nine months ended September 30, 2019 was impacted by two modifications during the first quarter and effective in 2019, a new vesting condition
that resulted in accelerated expense recognition.
|
(2) |
Acquisition, integration, and other costs of $9,602,000 and $18,787,000 for the three and nine months ended September 30, 2019, respectively, include net increases in the fair
value of contingent consideration liabilities for recently acquired companies of $4,441,000 and $2,283,000, respectively, and extraordinary legal expenses of approximately $2,100,000 and $6,700,000, respectively. Beginning in 2019, we
exclude the impact of extraordinary legal expenses from the calculation of adjusted EBITDA because we believe that these expenses are not indicative of the Company’s operating performance.
|
(3) |
During the third quarter of 2018, the Company recorded increases to its legal accruals established in connection with settlement agreements entered into during September and
October 2018 in two class actions related to wage and hour claims, both of which were paid during 2019. For the three months ended September 30, 2018, the increases amounted to $12,140,000. Since the settlements are largely unrelated to
the Company’s operating performance, we excluded the impact on adjusted EBITDA and adjusted diluted EPS for the three months ended September 30, 2018. Amounts recorded in prior quarters in these two class actions and legal accruals
related to other matters are immaterial and their impact was not excluded from adjusted EBITDA or adjusted diluted EPS.
|
(4) |
Adjusted EBITDA represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, acquisition and integration
costs, extraordinary legal expenses, legal settlement accrual increases and share-based compensation. Management believes that adjusted EBITDA provides an effective measure of the Company’s results, as it excludes certain items that
management believes are not indicative of the Company’s operating performance and is a measure used in the Company’s credit agreement and the indentures governing our 5.125% Senior Notes due 2024 and our 4.625% Senior Notes due 2027.
Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income as an indicator of operating performance. Although management believes that some
of the items excluded from adjusted EBITDA are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes adjusted EBITDA as an operating
performance measure in conjunction with GAAP measures such as net income.
|
(5) |
Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.
|
(6) |
Segment operating income represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, unallocated corporate
overhead, acquisition and integration costs, extraordinary legal expenses, legal settlement accrual increases and share-based compensation.
|
(7) |
Guidance percentage metrics are approximate.
|
|
Very truly yours,
|
|
|
|
|
|
/s/ Brian M. Scott |
|
|
Brian M. Scott |
|
|
Chief Financial Officer |
|
AMN Healthcare Services, Inc. |
cc:
|
Doug Jones
|
|
Securities and Exchange Commission
|
||
John C. Kennedy, Esq.
|
||
Paul, Weiss, Rifkind, Wharton & Garrison LLP
|